Glaucoma Therapeutics Strategic Industry Report 2024 - Growth in Specialty Eye Clinics Enhancing Treatment Reach

Global Glaucoma Therapeutics Market Poised for Growth; Set to Reach US$7.2 Billion by 2030


Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "Glaucoma Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global market for Glaucoma Therapeutics was estimated at US$5.7 Billion in 2023 and is projected to reach US$7.2 Billion by 2030, growing at a CAGR of 3.5% from 2023 to 2030.

The growth in the glaucoma therapeutics market is driven by several factors, including the aging population, innovative drug delivery methods, and heightened awareness about early detection. The increasing prevalence of glaucoma in elderly populations has led to sustained demand for treatment options. Innovations in drug delivery, such as sustained-release implants and microdosing technologies, are enhancing patient adherence and treatment effectiveness, making these options highly appealing.

Furthermore, public health campaigns and improvements in diagnostic technology have facilitated early detection, allowing patients to start treatment sooner and improving outcomes. These drivers collectively position the glaucoma therapeutics market for continued growth as it adapts to the needs of a growing and aging patient base.



Scope of the Study

The report analyzes the Glaucoma Therapeutics market, presented in terms of market value (US$ Million). The analysis covers the key segments and geographic regions outlined below.

Segments

  • Drug Class (Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Other Drug Classes)
  • Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Prostaglandins Analogs segment, which is expected to reach US$2.9 Billion by 2030 with a CAGR of a 3.2%. The Combination Drugs segment is also set to grow at 4.3% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.5 Billion in 2023, and China, forecasted to grow at an impressive 5.5% CAGR to reach $1.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Glaucoma Therapeutics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Glaucoma Therapeutics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Glaucoma Therapeutics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players in the Global Glaucoma Therapeutics Market such as Aerie Pharmaceuticals, Inc., Allergan, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Global Glaucoma Therapeutics Market report include:

  • Aerie Pharmaceuticals, Inc.
  • Allergan
  • Merck
  • Novartis
  • Pfizer, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Valeant Pharmaceuticals International, Inc.

Key Attributes:

Report AttributeDetails
No. of Pages193
Forecast Period2023 - 2030
Estimated Market Value (USD) in 2023$5.7 Billion
Forecasted Market Value (USD) by 2030$7.2 Billion
Compound Annual Growth Rate3.5%
Regions CoveredGlobal



Key Topics Covered:

1. MARKET OVERVIEW

  • World Market Trajectories
  • Glaucoma Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Rising Prevalence of Glaucoma and Related Eye Disorders
  • Growth in Geriatric Population Driving Treatment Demand
  • Advancements in Glaucoma Treatment Delivery Mechanisms
  • Increasing Availability of Minimally Invasive Glaucoma Surgeries
  • Expansion of Targeted Therapies for Progressive Glaucoma
  • Growth in Telemedicine and Online Consultations for Eye Care
  • Higher Demand for Combination Therapies in Glaucoma Treatment
  • Investment in R&D for Novel Glaucoma Medications
  • Rising Awareness Campaigns Boosting Early Diagnosis Rates
  • Development of Drug-Eluting Implants for Sustained Treatment
  • Increase in Accessibility of Glaucoma Therapies in Emerging Markets
  • Growth in Specialty Eye Clinics Enhancing Treatment Reach

4. GLOBAL MARKET PERSPECTIVE

For more information about this report visit https://www.researchandmarkets.com/r/ffe7dz

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

 
Glaucoma Therapeutics Market

Contact Data